Strategic Partnership Forms to Accelerate Drug Development

Pharmaceutical Technology Editors

REPROCELL Europe has announced a strategic partnership with Medicines Discovery Catapult, as part of the virtual R&D platform that is aimed at supporting drug development.

Human tissue research company, REPROCELL Europe, has announced a strategic partnership with Medicines Discovery Catapult, as part of the virtual R&D platform that is aimed at supporting drug development.

“REPROCELL is recognized in the use of ethically-sourced human fresh tissue to better predict drug efficacy and safety during pre-clinical drug development,” said David Bunton, chief executive officer, REPROCELL Europe, in a March 12, 2019 press statement. “We are excited to be working closely with the Medicines Discovery Catapult and to be part of a select group of companies developing innovative approaches to drug discovery. We hope that our combined services will accelerate drug development to the benefit of many U[nited] K[ingdom] biotechs.”

“Ethically-sourced human tissue samples are such an important resource for the prediction of efficacy and safety of novel drug compounds and are becoming increasingly important in the area of precision medicine,” added Dr Karen Bingham, chief operating officer, REPROCELL Europe. “It's crucial that the NHS, industry and academia work together through collaborations such as Medicines Discovery Catapult in order to maximize use of this precious resource.”

Medicine Discovery Catapult’s virtual R&D platform uses a national network of industry-skilled consultants and service providers to support UK small-to-medium enterprises develop and execute drug discovery projects. Within the virtual R&D platform, REPROCELL will provide custom drug discovery assays using live human tissues that can be used to improve the prediction of drug safety and efficacy.

Source: REPROCELL